Literature DB >> 22165036

Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.

Eugenia Oviedo-Joekes1, David C Marsh, Daphne Guh, Suzanne Brissette, Martin T Schechter.   

Abstract

BACKGROUND: Data on conversion ratios for switching opioids in substitution treatment are limited.
METHODS: Data were obtained from a randomized controlled trial among long-term opioid-dependent patients conducted in Vancouver and Montreal, Canada. Patients received diacetylmorphine (n = 115) or hydromorphone (n = 25) on a double-blind basis, on a 1:3 potency ratio with individually adjusted dosage, both injectable.
RESULTS: Average daily dosages of hydromorphone and diacetylmorphine prescribed were 212.6 mg and 454.0 mg, respectively; potency ratio was 1:2.0-2.2 at different dose ranges.
CONCLUSIONS: Studies using hydromorphone as a diacetylmorphine equivalent should consider the ratio found in this study to achieve equipotency and maintain the blinding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22165036     DOI: 10.5055/jom.2011.0078

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  3 in total

1.  Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.

Authors:  Kelly E Dunn; Bruna Brands; David C Marsh; George E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2017-12-21       Impact factor: 4.530

2.  Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.

Authors:  Kirsten I Marchand; Eugenia Oviedo-Joekes; Daphne Guh; Suzanne Brissette; David C Marsh; Martin T Schechter
Journal:  BMC Health Serv Res       Date:  2011-07-26       Impact factor: 2.655

3.  Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder.

Authors:  Eugenia Oviedo-Joekes; Heather Palis; Daphne Guh; David C Marsh; Scott MacDonald; Scott Harrison; Suzanne Brissette; Aslam H Anis; Martin T Schechter
Journal:  J Addict Med       Date:  2019 Sep/Oct       Impact factor: 3.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.